Study shows biocept's assays are viable and sensitive for detecting tumor cells and biomarkers in the cerebrospinal fluid of patients with breast and lung cancer that has metastasized to the central nervous system

San diego, nov. 20, 2020 /prnewswire/ -- biocept, inc. (nasdaq: bioc), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study...
BIOC Ratings Summary
BIOC Quant Ranking